IMC Chicago
NKTR icon

IMC Chicago’s Nektar Therapeutics NKTR Stock Holding History

IMC Chicago’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$7.21M Buy
119,100
+55,400
+87% +$3.89M ﹤0.01% 1914
2026
Q2 		$4.45M Buy
63,700
+43,200
+211% +$3.16M ﹤0.01% 2215
2026
Q1 		$1.47M Buy
20,500
+8,600
+72% +$490K ﹤0.01% 2876
2025
Q4 		$503K Buy
+11,900
New +$666K ﹤0.01% 3472

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Two Seas Capital
Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Emerald Advisers
Emerald Advisers Leola, Pennsylvania $3.64B AUM 71.19% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Emerald Mutual Fund Advisers Trust
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.45B AUM 70.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

IMC Chicago's NKTR Position: Q3 2026 in Review

IMC Chicago increased its Nektar Therapeutics (NKTR) stake by 138% in Q3 2026, buying an estimated $2.17M and bringing the position to 53,290 shares worth $3.23M. The position accounts for ﹤0.01% of the portfolio, ranked #2670.

IMC Chicago first reported a position in NKTR in Q1 2026 and has held it in 3 quarters since. 77 funds tracked by Wall St. Rank hold NKTR as of Q3 2026.

  • IMC Chicago held 53,290 shares of Nektar Therapeutics worth $3.23M as of Q3 2026.
  • IMC Chicago bought 30,878 Nektar Therapeutics shares in Q3 2026, an estimated $2.17M.
  • Nektar Therapeutics made up ﹤0.01% of IMC Chicago's portfolio in Q3 2026, its #2670 holding.
  • IMC Chicago first reported a position in Nektar Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 77 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2026.

Based on IMC Chicago's 13F filing for Q3 2026, filed 5 Nov 2026.